Carly P. Smith, PhD and Daniel R. George, PhD, MSc
Invisibility of racial inequity and gender inclusion in clinical research means key features of disease etiology and symptom presentation are unaccounted for.
AMA J Ethics. 2021;23(7):E563-568. doi:
10.1001/amajethics.2021.563.
Charles E. Binkley, MD, Michael S. Politz, MA, and Brian P. Green, PhD
If the safe-and-effective standard for judging devices’ potential as therapy or enhancement is inadequate, one might wonder whether BCI regulation should be overseen by the FDA.
AMA J Ethics. 2021;23(9):E745-749. doi:
10.1001/amajethics.2021.745.
Dr Charles Binkley joins Ethics Talk to discuss his article, coauthored with Michael Politz and Dr Brian Green: "Who, If Not the FDA, Should Regulate Implantable Brain-Computer Interface Devices?"
Deborah M. Eng, MS, MA and Scott J. Schweikart, JD, MBE
A just culture perspective suggests that punitive responses to those who err should be reserved for those who have willfully and irremediably caused harm.
AMA J Ethics. 2020;22(9):E779-783. doi:
10.1001/amajethics.2020.779.
Stephanie L. Samuels, MD and Wilma C. Rossi, MD, MBE
When a parent resists a physician's recommendation for a pediatric patient, physician-parent partnering can promote the patient's best interest and help encourage lifestyle changes.
AMA J Ethics. 2018;20(12):E1126-1132. doi:
10.1001/amajethics.2018.1126
Jane Bartels, MBBS and Christopher J. Ryan, MBBS, MHL
When patients cannot give informed consent or refusal for antipsychotic medication, physicians must meet specific criteria to justify temporarily withholding a diagnosis.
AMA J Ethics. 2018;20(12):E1119-1125. doi:
10.1001/amajethics.2018.1119.